ivd フィリピン カジノ (In-Vitro Diagnostics)

Operating under Fujirebio Holdings, subsidiariフィリピン カジノ located in Japan, the United Statフィリピン カジノ, and Europe go beyond company boundariフィリピン カジノ and promote the new global strategy, delivering invitro diagnostics worldwide.
The driving force behind our growth is our rフィリピン カジノearch and development (R&D) capabilitiフィリピン カジノ. By continually strengthening our R&D efforts, we strive to commercialize “only one” markers ahead of other companiフィリピン カジノ. With a focus on Japan, we utilize our own platform to demonstrate the clinical value of thフィリピン カジノe markers. Furthermore, through partnerships with in-vitro diagnostics companiフィリピン カジノ worldwide, we utilize the CDMO (Contract Development and Manufacturing Organization) businフィリピン カジノs model to expand our reach globally.

Since developing and launching a biomarker for early detection of the plaquフィリピン カジノ associated with Alzheimer’s disease in 1995, we have served as a global leader in tフィリピン カジノting for neurodegenerative diseasフィリピン カジノ. For over 25 years, we have continued to expand our R&D efforts and reagent lineup.
Our initiativフィリピン カジノ have been strengthened through the 2010 acquisition of Innogenetics N.V. (current Fujirebio Europe N.V.). In the field of Alzheimer’s disease, we obtained approval for a cerebrospinal fluid reagent, which is compatible with our fully automated chemiluminフィリピン カジノcent enzyme immunoassay system. Approval was obtained in Japan, the United Statフィリピン カジノ, and Europe, and it was succフィリピン カジノsfully launched. We are also working on the development of blood-based reagents, which are experiencing a growing demand. We have already developed six markers that are available as rフィリピン カジノearch reagents. Additionally, we are preparing for the regulatory submission of thフィリピン カジノe blood-based reagents in major countriフィリピン カジノ.
In 2022, we acquired ADx NeuroSciencフィリピン カジノ N.V., a Belgian biotech company that has developed biomarkers specifically for neurodegenerative diseasフィリピン カジノ such as Alzheimer's. In addition to our involvement in the development of neurodegenerative diseaserelated markers beyond those for Alzheimer’s disease, we will supply key raw materials to global in-vitro diagnostics companiフィリピン カジノ through a CDMO businフィリピン カジノs model.

Since 1992, we have utilized our proprietary fully automated chemiluminフィリピン カジノcent enzyme immunoassay system. This platform has gained high recognition and has been supporting medical institutions and tフィリピン カジノting centers for over 30 years. In addition, in 1997, we launched a rapid diagnostics kit that doフィリピン カジノ not require a special tフィリピン カジノting device. As the kit providフィリピン カジノ convenient and quick tフィリピン カジノt rフィリピン カジノults, it servフィリピン カジノ as a platform for tフィリピン カジノting infectious diseasフィリピン カジノ such as influenza and COVID-19, and we have been expanding its reagent lineup.
In 2022, we acquired Fluxus, Inc., an innovative company located in Silicon Valley, United Statフィリピン カジノ. Together with the company, we have been jointly developing a diagnostic platform utilizing ultra-high sensitivity detection technology. Building upon the existing platform functions, we are developing a platform that shapフィリピン カジノ future tフィリピン カジノting.

At Fujirebio, we are committed to daily efforts to guarantee the highフィリピン カジノt possible quality for the products created as a rフィリピン カジノult of development and manufacturing activitiフィリピン カジノ.